Optic nerve impairment along with differences in the field of vision are defining characteristics of glaucoma, a progressive optic neuropathy. It is one of the main global causes of permanent blindness. Elevated intraocular pressure (IOP), which can be caused by overproduction or poor aqueous humor outflow, is the main risk factor for glaucoma. Even while a high IOP is a significant risk factor, some people can get glaucoma while having a normal IOP, which suggests that there may be more underlying causes such vascular insufficiency or genetic susceptibility. A thorough eye examination to evaluate the health of the optic nerve, visual field tests, and IOP measurement are usually required for the diagnosis. In order to stop the disease's progression and protect vision, treatment seeks to lower IOP. This thesis investigates the effectiveness of chitosan polymer-based sustained-release ocular medication delivery system, Pilocarpine HCl ocusert, in the management of glaucoma. Increased intraocular pressure which causes damage to the optic nerve is a sign of glaucoma, one of the major causes of permanent blindness. The Ocusert device releases pilocarpine HCl slowly over time, thereby increasing medicine absorption and retaining its therapeutic concentration in the eye. Reducing the frequency of administration while maintaining consistent treatment effects is the goal of this continuous delivery strategy. Through clinical trials and pharmacokinetic analysis, the study assesses the efficacy of the device, ocular tolerance, and patient compliance. The findings provide information for improving glaucoma treatment plans using cutting-edge medication delivery systems.